APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Inactivated Vaccine Market Analysis and Forecast 2026-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchInactivated Vaccine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Inactivated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Inactivated Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Inactivated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Inactivated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Inactivated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Inactivated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Inactivated Vaccine include Johnson & Johnson(U.S.), Merck & Co(U.S.), Pfizer(U.S.), GlaxoSmithKline(U.K.), Serum Institute of India Pvt(India), Sanofi Pasteur(France), MedImmune(U.S.), Emergent BioSolutions(U.S.) and CSL Limited(Australia), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Inactivated Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Inactivated Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Inactivated Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inactivated Vaccine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Inactivated Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Inactivated Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Inactivated Vaccine Segment by Company

Johnson & Johnson(U.S.)

Merck & Co(U.S.)

Pfizer(U.S.)

GlaxoSmithKline(U.K.)

Serum Institute of India Pvt(India)

Sanofi Pasteur(France)

MedImmune(U.S.)

Emergent BioSolutions(U.S.)

CSL Limited(Australia)

Astellas Pharma(Japan)

Inactivated Vaccine Segment by Type

Children Inactivated Vaccine

Adult Inactivated Vaccine

Inactivated Vaccine Segment by Application

Hospital

Medical Center

Inactivated Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Inactivated Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Inactivated Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Vaccine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Inactivated Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Children Inactivated Vaccine Major Player Table 3. Adult Inactivated Vaccine Major Player Table 4. Global Inactivated Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Medical Center Major Player Table 7. Inactivated Vaccine Industry Trends Table 8. Inactivated Vaccine Industry Drivers Table 9. Inactivated Vaccine Industry Opportunities and Challenges Table 10. Inactivated Vaccine Industry Restraints Table 11. Global Inactivated Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Inactivated Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Inactivated Vaccine Market Share by Region (2021-2026) Table 14. Global Inactivated Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Inactivated Vaccine Market Share by Region (2027-2032) Table 16. Global Inactivated Vaccine Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Inactivated Vaccine Revenue Market Share by Players (2021-2026) Table 18. Global Inactivated Vaccine Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Inactivated Vaccine Key Players Headquarters & Area Served Table 20. Global Inactivated Vaccine Players, Product Type & Application Table 21. Global Inactivated Vaccine Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Inactivated Vaccine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Inactivated Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Inactivated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Inactivated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Inactivated Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Inactivated Vaccine Revenue Market Share by Type (2027-2032) Table 29. Global Inactivated Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Inactivated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Inactivated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Inactivated Vaccine Revenue Market Share by Application (2021-2026) Table 33. Global Inactivated Vaccine Revenue Market Share by Application (2027-2032) Table 34. Johnson & Johnson(U.S.) Company Information Table 35. Johnson & Johnson(U.S.) Business Overview Table 36. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio Table 38. Johnson & Johnson(U.S.) Recent Development Table 39. Merck & Co(U.S.) Company Information Table 40. Merck & Co(U.S.) Business Overview Table 41. Merck & Co(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Merck & Co(U.S.) Inactivated Vaccine Product Portfolio Table 43. Merck & Co(U.S.) Recent Development Table 44. Pfizer(U.S.) Company Information Table 45. Pfizer(U.S.) Business Overview Table 46. Pfizer(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Pfizer(U.S.) Inactivated Vaccine Product Portfolio Table 48. Pfizer(U.S.) Recent Development Table 49. GlaxoSmithKline(U.K.) Company Information Table 50. GlaxoSmithKline(U.K.) Business Overview Table 51. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio Table 53. GlaxoSmithKline(U.K.) Recent Development Table 54. Serum Institute of India Pvt(India) Company Information Table 55. Serum Institute of India Pvt(India) Business Overview Table 56. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio Table 58. Serum Institute of India Pvt(India) Recent Development Table 59. Sanofi Pasteur(France) Company Information Table 60. Sanofi Pasteur(France) Business Overview Table 61. Sanofi Pasteur(France) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio Table 63. Sanofi Pasteur(France) Recent Development Table 64. MedImmune(U.S.) Company Information Table 65. MedImmune(U.S.) Business Overview Table 66. MedImmune(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. MedImmune(U.S.) Inactivated Vaccine Product Portfolio Table 68. MedImmune(U.S.) Recent Development Table 69. Emergent BioSolutions(U.S.) Company Information Table 70. Emergent BioSolutions(U.S.) Business Overview Table 71. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio Table 73. Emergent BioSolutions(U.S.) Recent Development Table 74. CSL Limited(Australia) Company Information Table 75. CSL Limited(Australia) Business Overview Table 76. CSL Limited(Australia) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. CSL Limited(Australia) Inactivated Vaccine Product Portfolio Table 78. CSL Limited(Australia) Recent Development Table 79. Astellas Pharma(Japan) Company Information Table 80. Astellas Pharma(Japan) Business Overview Table 81. Astellas Pharma(Japan) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio Table 83. Astellas Pharma(Japan) Recent Development Table 84. North America Inactivated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 85. North America Inactivated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 86. North America Inactivated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 87. North America Inactivated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 88. North America Inactivated Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America Inactivated Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 90. North America Inactivated Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 91. Europe Inactivated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 92. Europe Inactivated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 93. Europe Inactivated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 94. Europe Inactivated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 95. Europe Inactivated Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe Inactivated Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 97. Europe Inactivated Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 98. China Inactivated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 99. China Inactivated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 100. China Inactivated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 101. China Inactivated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Inactivated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 103. Asia Inactivated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 104. Asia Inactivated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 105. Asia Inactivated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Inactivated Vaccine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Asia Inactivated Vaccine Revenue by Region (US$ Million) & (2021-2026) Table 108. Asia Inactivated Vaccine Revenue by Region (US$ Million) & (2027-2032) Table 109. SAMEA Inactivated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 110. SAMEA Inactivated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 111. SAMEA Inactivated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 112. SAMEA Inactivated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 113. SAMEA Inactivated Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. SAMEA Inactivated Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 115. SAMEA Inactivated Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Inactivated Vaccine Image Figure 2. Global Inactivated Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inactivated Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Children Inactivated Vaccine Image Figure 5. Adult Inactivated Vaccine Image Figure 6. Global Inactivated Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Inactivated Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Medical Center Image Figure 10. Global Inactivated Vaccine Market Size (US$ Million) & (2021-2032) Figure 11. Global Inactivated Vaccine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Inactivated Vaccine Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Inactivated Vaccine Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Inactivated Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Inactivated Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Inactivated Vaccine Revenue Market Share by Type (2021-2032) Figure 18. Global Inactivated Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Inactivated Vaccine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Inactivated Vaccine Revenue Market Share by Application (2021-2032) Figure 21. North America Inactivated Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Inactivated Vaccine Revenue Share by Type (2021-2032) Figure 23. North America Inactivated Vaccine Revenue Share by Application (2021-2032) Figure 24. North America Inactivated Vaccine Revenue Share by Country (2021-2032) Figure 25. United States Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Inactivated Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Inactivated Vaccine Revenue Share by Type (2021-2032) Figure 30. Europe Inactivated Vaccine Revenue Share by Application (2021-2032) Figure 31. Europe Inactivated Vaccine Revenue Share by Country (2021-2032) Figure 32. Germany Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Inactivated Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Inactivated Vaccine Revenue Share by Type (2021-2032) Figure 42. China Inactivated Vaccine Revenue Share by Application (2021-2032) Figure 43. Asia Inactivated Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Inactivated Vaccine Revenue Share by Type (2021-2032) Figure 45. Asia Inactivated Vaccine Revenue Share by Application (2021-2032) Figure 46. Asia Inactivated Vaccine Revenue Share by Region (2021-2032) Figure 47. Japan Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Inactivated Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Inactivated Vaccine Revenue Share by Type (2021-2032) Figure 55. SAMEA Inactivated Vaccine Revenue Share by Application (2021-2032) Figure 56. SAMEA Inactivated Vaccine Revenue Share by Country (2021-2032) Figure 57. Brazil Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Inactivated Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Children Inactivated Vaccine
  • Adult Inactivated Vaccine
Applications
  • Hospital
  • Medical Center
Companies covered
  • Johnson & Johnson(U.S.)
  • Merck & Co(U.S.)
  • Pfizer(U.S.)
  • GlaxoSmithKline(U.K.)
  • Serum Institute of India Pvt(India)
  • Sanofi Pasteur(France)
  • MedImmune(U.S.)
  • Emergent BioSolutions(U.S.)
  • CSL Limited(Australia)
  • Astellas Pharma(Japan)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Inactivated Vaccine Market by Type
  3. 1.2.1 Global Inactivated Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Children Inactivated Vaccine
  5. 1.2.3 Adult Inactivated Vaccine
  6. 1.3 Inactivated Vaccine Market by Application
  7. 1.3.1 Global Inactivated Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Medical Center
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Inactivated Vaccine Market Dynamics
  1. 2.1 Inactivated Vaccine Industry Trends
  2. 2.2 Inactivated Vaccine Industry Drivers
  3. 2.3 Inactivated Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Vaccine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Inactivated Vaccine Market Perspective (2021-2032)
  2. 3.2 Global Inactivated Vaccine Growth Trends by Region
  3. 3.2.1 Global Inactivated Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Inactivated Vaccine Market Size by Region (2021-2026)
  5. 3.2.3 Global Inactivated Vaccine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Inactivated Vaccine Revenue by Players
  2. 4.1.1 Global Inactivated Vaccine Revenue by Players (2021-2026)
  3. 4.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Inactivated Vaccine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Inactivated Vaccine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Inactivated Vaccine Key Players Headquarters & Area Served
  7. 4.4 Global Inactivated Vaccine Players, Product Type & Application
  8. 4.5 Global Inactivated Vaccine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Inactivated Vaccine Market CR5 and HHI
  11. 4.6.3 2025 Inactivated Vaccine Tier 1, Tier 2, and Tier 3
5 Inactivated Vaccine Market Size by Type
  1. 5.1 Global Inactivated Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Inactivated Vaccine Revenue by Type (2021-2032)
  3. 5.3 Global Inactivated Vaccine Revenue Market Share by Type (2021-2032)
6 Inactivated Vaccine Market Size by Application
  1. 6.1 Global Inactivated Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Inactivated Vaccine Revenue by Application (2021-2032)
  3. 6.3 Global Inactivated Vaccine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Johnson & Johnson(U.S.)
  2. 7.1.1 Johnson & Johnson(U.S.) Company Information
  3. 7.1.2 Johnson & Johnson(U.S.) Business Overview
  4. 7.1.3 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio
  6. 7.1.5 Johnson & Johnson(U.S.) Recent Developments
  7. 7.2 Merck & Co(U.S.)
  8. 7.2.1 Merck & Co(U.S.) Company Information
  9. 7.2.2 Merck & Co(U.S.) Business Overview
  10. 7.2.3 Merck & Co(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co(U.S.) Inactivated Vaccine Product Portfolio
  12. 7.2.5 Merck & Co(U.S.) Recent Developments
  13. 7.3 Pfizer(U.S.)
  14. 7.3.1 Pfizer(U.S.) Company Information
  15. 7.3.2 Pfizer(U.S.) Business Overview
  16. 7.3.3 Pfizer(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer(U.S.) Inactivated Vaccine Product Portfolio
  18. 7.3.5 Pfizer(U.S.) Recent Developments
  19. 7.4 GlaxoSmithKline(U.K.)
  20. 7.4.1 GlaxoSmithKline(U.K.) Company Information
  21. 7.4.2 GlaxoSmithKline(U.K.) Business Overview
  22. 7.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio
  24. 7.4.5 GlaxoSmithKline(U.K.) Recent Developments
  25. 7.5 Serum Institute of India Pvt(India)
  26. 7.5.1 Serum Institute of India Pvt(India) Company Information
  27. 7.5.2 Serum Institute of India Pvt(India) Business Overview
  28. 7.5.3 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio
  30. 7.5.5 Serum Institute of India Pvt(India) Recent Developments
  31. 7.6 Sanofi Pasteur(France)
  32. 7.6.1 Sanofi Pasteur(France) Company Information
  33. 7.6.2 Sanofi Pasteur(France) Business Overview
  34. 7.6.3 Sanofi Pasteur(France) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio
  36. 7.6.5 Sanofi Pasteur(France) Recent Developments
  37. 7.7 MedImmune(U.S.)
  38. 7.7.1 MedImmune(U.S.) Company Information
  39. 7.7.2 MedImmune(U.S.) Business Overview
  40. 7.7.3 MedImmune(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 MedImmune(U.S.) Inactivated Vaccine Product Portfolio
  42. 7.7.5 MedImmune(U.S.) Recent Developments
  43. 7.8 Emergent BioSolutions(U.S.)
  44. 7.8.1 Emergent BioSolutions(U.S.) Company Information
  45. 7.8.2 Emergent BioSolutions(U.S.) Business Overview
  46. 7.8.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio
  48. 7.8.5 Emergent BioSolutions(U.S.) Recent Developments
  49. 7.9 CSL Limited(Australia)
  50. 7.9.1 CSL Limited(Australia) Company Information
  51. 7.9.2 CSL Limited(Australia) Business Overview
  52. 7.9.3 CSL Limited(Australia) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 CSL Limited(Australia) Inactivated Vaccine Product Portfolio
  54. 7.9.5 CSL Limited(Australia) Recent Developments
  55. 7.10 Astellas Pharma(Japan)
  56. 7.10.1 Astellas Pharma(Japan) Company Information
  57. 7.10.2 Astellas Pharma(Japan) Business Overview
  58. 7.10.3 Astellas Pharma(Japan) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio
  60. 7.10.5 Astellas Pharma(Japan) Recent Developments
8 North America
  1. 8.1 North America Inactivated Vaccine Revenue (2021-2032)
  2. 8.2 North America Inactivated Vaccine Revenue by Type (2021-2032)
  3. 8.2.1 North America Inactivated Vaccine Revenue by Type (2021-2026)
  4. 8.2.2 North America Inactivated Vaccine Revenue by Type (2027-2032)
  5. 8.3 North America Inactivated Vaccine Revenue Share by Type (2021-2032)
  6. 8.4 North America Inactivated Vaccine Revenue by Application (2021-2032)
  7. 8.4.1 North America Inactivated Vaccine Revenue by Application (2021-2026)
  8. 8.4.2 North America Inactivated Vaccine Revenue by Application (2027-2032)
  9. 8.5 North America Inactivated Vaccine Revenue Share by Application (2021-2032)
  10. 8.6 North America Inactivated Vaccine Revenue by Country
  11. 8.6.1 North America Inactivated Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Inactivated Vaccine Revenue by Country (2021-2026)
  13. 8.6.3 North America Inactivated Vaccine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Inactivated Vaccine Revenue (2021-2032)
  2. 9.2 Europe Inactivated Vaccine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Inactivated Vaccine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Inactivated Vaccine Revenue by Type (2027-2032)
  5. 9.3 Europe Inactivated Vaccine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Inactivated Vaccine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Inactivated Vaccine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Inactivated Vaccine Revenue by Application (2027-2032)
  9. 9.5 Europe Inactivated Vaccine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Inactivated Vaccine Revenue by Country
  11. 9.6.1 Europe Inactivated Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Inactivated Vaccine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Inactivated Vaccine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Inactivated Vaccine Revenue (2021-2032)
  2. 10.2 China Inactivated Vaccine Revenue by Type (2021-2032)
  3. 10.2.1 China Inactivated Vaccine Revenue by Type (2021-2026)
  4. 10.2.2 China Inactivated Vaccine Revenue by Type (2027-2032)
  5. 10.3 China Inactivated Vaccine Revenue Share by Type (2021-2032)
  6. 10.4 China Inactivated Vaccine Revenue by Application (2021-2032)
  7. 10.4.1 China Inactivated Vaccine Revenue by Application (2021-2026)
  8. 10.4.2 China Inactivated Vaccine Revenue by Application (2027-2032)
  9. 10.5 China Inactivated Vaccine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Inactivated Vaccine Revenue (2021-2032)
  2. 11.2 Asia Inactivated Vaccine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Inactivated Vaccine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Inactivated Vaccine Revenue by Type (2027-2032)
  5. 11.3 Asia Inactivated Vaccine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Inactivated Vaccine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Inactivated Vaccine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Inactivated Vaccine Revenue by Application (2027-2032)
  9. 11.5 Asia Inactivated Vaccine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Inactivated Vaccine Revenue by Country
  11. 11.6.1 Asia Inactivated Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Inactivated Vaccine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Inactivated Vaccine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Inactivated Vaccine Revenue (2021-2032)
  2. 12.2 SAMEA Inactivated Vaccine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Inactivated Vaccine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Inactivated Vaccine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Inactivated Vaccine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Inactivated Vaccine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Inactivated Vaccine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Inactivated Vaccine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Inactivated Vaccine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Inactivated Vaccine Revenue by Country
  11. 12.6.1 SAMEA Inactivated Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Inactivated Vaccine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Inactivated Vaccine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst